Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan

Modern Rheumatology

Volumn 22, Issue 4, 2012, Pages 491-497

  Yokota, Shumpei ^a   Imagawa, Tomoyuki ^a   Murata, Takuji ^b   Tomiita, Minako ^c   Itoh, Yasuhiko ^d   Fujikawa, Satoshi ^e   Takei, Syuji ^f   Mori, Masaaki ^g  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f KAGOSHIMA UNIVERSITY   (Japan)

^g YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Anti TNF monoclonal antibody (adalimumab); Juvenile idiopathic arthritis; Methotrexate; Steroids

Indexed keywords

ADALIMUMAB; STEROID;

DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG USE; FEVER; HEADACHE; HUMAN; HYPERSENSITIVITY; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; JAPAN; JUVENILE RHEUMATOID ARTHRITIS; PAIN; PHARYNGITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DRUG EVALUATION; HUMANS; JAPAN; JOINTS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 84865371242     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0561-1     Document Type: Review

References (15)

1. Yokota S, Mori M, Imagawa T, Takei S, Murata T, Tomiita M, et al. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007). Mod Rheumatol. 2007;17: 353-63. (Pubitemid 47593481)
2. van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-16. (Pubitemid 38530193)
3. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136-46. (Pubitemid 44051069)
4. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-38. (Pubitemid 351650483)
5. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, et al. Impact of adalimumab treatment on patientreported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18:341-50. (Pubitemid 350223202)
6. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810-20.
7. Miyasaka N. The CHANGE Study Investigator. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252-62.
8. Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37:299-310.
9. Cassidy JT. Chronic arthritis, poly arthritis, oligoarthritis, systemic arthritis. In: Cassidy JT, Petty RE, Laxer RM, Linsley CB, editors. Textbook of Pediatric Rheumatology. 5th ed. ed. Philadelphia: Elsevier Saunders; 2005. p. 206-303.
10. Harrington J. Developmental issues in adolescence and the impact of rheumatic disease. In: Isenberg DA, Miller JJ, editors. Adolescent Rheumatology. London: Martin Dunitz; 2000.21-34.
11. Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Pattern of expression of tumor necrosis factor a, tumor necrosis factor b, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum. 1996;39:1703-10. (Pubitemid 26331024)
12. Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol. 1994;96:260-6. (Pubitemid 24213832)
13. Fink CW. Proposal for the development of classification criteria for the idiopathic arthritides of childhood. J Rheumatol. 1995;22:1566-9.
14. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
15. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202-9. (Pubitemid 27430130)